UroGen shareholders reject say-on-pay and compensation policy; approve equity plan increase

UroGen Pharma Ltd.

Advisory vote on executive compensation failed: 5.7M against vs 4.2M for.
Amendment to compensation policy under Israeli law not approved: 2.5M for, 4.9M against.
Equity plan amendment (increase by 400K shares) approved narrowly: 5.3M for, 4.5M against.
PricewaterhouseCoopers ratified as independent auditor with 14.2M votes for.
All six director nominees elected, with Arie Belldegrun receiving 7.5M votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.